Document Detail

Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.
MedLine Citation:
PMID:  7974318     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The efficacy of an antibiotic is related to its concentration at the site of infection. Previous studies of the concentrations of amoxycillin and clavulanic acid (co-amoxiclav) in respiratory secretions or whole lung tissue have suffered from methodological problems. The concentration of amoxycillin and clavulanic acid was determined in bronchial mucosal biopsy samples obtained at bronchoscopy following five different dosing regimens. METHODS: Bronchial biopsy and serum samples were obtained from 50 patients undergoing diagnostic bronchoscopy. Ten patients each received 375 mg, 625 mg, 750 mg, and 3.25 g oral, and 1.2 g intravenous co-amoxiclav 1-3 hours before bronchoscopy. The concentrations of clavulanic acid and amoxycillin were determined by high performance liquid chromatography using a microbore column, solid phase extraction, and preconcentration to improve sensitivity tenfold over previous methods. RESULTS: Concentrations of both clavulanic acid and amoxycillin in bronchial mucosa were dose related and were well above the MIC90 of co-amoxiclav for the common bacterial respiratory pathogens including Haemophilus influenzae, Micrococcus catarrhalis and Streptococcus pneumoniae for all dosing regimens. Mean mucosal levels were 200% and 118% of the corresponding serum levels for amoxycillin and clavulanic acid respectively. CONCLUSIONS: Amoxycillin and clavulanic acid are concentrated in bronchial mucosa and, even at the lowest dose of 375 mg orally, are likely to produce tissue levels in the lung sufficient to inhibit all the common community acquired respiratory pathogens.
I M Gould; G Harvey; D Golder; T M Reid; S J Watt; J A Friend; J S Legge; J G Douglas
Related Documents :
6106668 - The granulation of ternary mixtures: the effect of the wettability of the powders.
16880248 - Topical ciprofloxacin/dexamethasone superior to oral amoxicillin/clavulanic acid in acu...
19719168 - Nickel-catalyzed cycloaddition of salicylic acid ketals to alkynes via elimination of k...
16332128 - Salicylate activity. 1. protection of plants from paraquat injury.
2674238 - Trichloroacetic acid peels revisited.
25266238 - Membrane fatty acid compositions and cold-induced responses in tetraploid and hexaploid...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thorax     Volume:  49     ISSN:  0040-6376     ISO Abbreviation:  Thorax     Publication Date:  1994 Oct 
Date Detail:
Created Date:  1994-12-06     Completed Date:  1994-12-06     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0417353     Medline TA:  Thorax     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  999-1001     Citation Subset:  IM    
Department of Clinical Microbiology, Aberdeen Royal Infirmary, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amoxicillin / administration & dosage,  analysis,  pharmacokinetics
Amoxicillin-Potassium Clavulanate Combination
Bronchi / metabolism*
Chromatography, High Pressure Liquid
Clavulanic Acids / administration & dosage,  analysis,  pharmacokinetics
Drug Administration Schedule
Drug Therapy, Combination / administration & dosage,  analysis,  pharmacokinetics*
Mucous Membrane / metabolism
Respiratory Tract Infections / prevention & control
Sensitivity and Specificity
Reg. No./Substance:
0/Clavulanic Acids; 26787-78-0/Amoxicillin; 74469-00-4/Amoxicillin-Potassium Clavulanate Combination
Comment In:
Thorax. 1995 Apr;50(4):429   [PMID:  7785023 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of angiotensin converting enzyme inhibition on sodium excretion in patients with hypoxaemic ...
Next Document:  Factors involved in the plasminogen activation system in human breast tumours.